- Home
- CRBU vs UNCY Comparison
CRBU vs UNCY Comparison
Compare CRBU & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRBU | UNCY |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.3M | 150.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRBU | UNCY |
|---|---|---|
| Price | $1.24 | $4.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $11.86 | ★ $29.60 |
| AVG Volume (30 Days) | ★ 1.0M | 767.1K |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | $128.04 | N/A |
| Revenue Next Year | $17.09 | $52,701.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $3.93 |
| 52 Week High | $3.53 | $8.74 |
Technical Indicators
Market Signals| Indicator | CRBU | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 40.81 |
| Support Level | N/A | $3.93 |
| Resistance Level | $1.74 | $5.86 |
| Average True Range (ATR) | 0.05 | 0.20 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 32.14 | 38.32 |
Price Performance
Historical ComparisonAbout CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.